ImmunoGen maintained at sector perform by RBC

RBC Capital Markets analyst Jason Kantor kept ImmunoGen, Inc. at sector perform, speculative risk, due to a lack of significant near-term news flow. The analyst said he expects some early data over the next few months, including phase 1 data from its clinical candidates huN901-DM1 and huC242-DM4 in solid tumors, but there may not be significant efficacy at these low doses. Shares of the Cambridge, Mass.-based pharmaceutical company were up 11 cents, or 2.7%, at $4.18, on volume of 46,190 shares versus the three-month running average of 98,762 shares. (Nasdaq: IMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.